RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis.

Autor: Ben-Crentsil NA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Mohammed Ismail W; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota., Balasis ME; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Newman H; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Quintana A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Binder M; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Kruer T; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Neupane S; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Ferrall-Fairbanks MC; J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida.; University of Florida Health Cancer Center, University of Florida, Gainesville, Florida., Fernandez J; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Lasho TL; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Finke CM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Ibrahim ML; Department of Immunology, Moffitt Cancer Center, Tampa, Florida.; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt., McGraw KL; National Institutes of Health, Bethesda, Maryland., Wysota M; Department of Medical Oncology, Montefiore Medical Center, Bronx, New York., Aldrich AL; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Ryder CB; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Letson CT; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Traina J; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., McLemore AF; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Droin N; NSERM U1287, Gustave Roussy Cancer Center, Villejuif, France., Shastri A; Department of Medical Oncology, Montefiore Medical Center, Bronx, New York., Yun S; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Solary E; NSERM U1287, Gustave Roussy Cancer Center, Villejuif, France., Sallman DA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida., Beg AA; Department of Immunology, Moffitt Cancer Center, Tampa, Florida., Ma L; Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, Texas., Gaspar-Maia A; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Dec 02; Vol. 14 (12), pp. 2509-2531.

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.

Autor: Letson CT; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Balasis ME; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Newman H; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Binder M; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota., Vedder A; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Kinose F; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Ball M; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Kruer T; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Quintana A; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Lasho TL; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota., Finke CM; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota., Almada LL; Division of Oncology Research, Schulze Center for Novel Therapeutics, Department of Oncology, Mayo Clinic, Rochester, Minnesota., Grants JM; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC., Zhang G; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Fernandez-Zapico ME; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Gaspar-Maia A; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota., Lancet J; Malignant Hematology Department, Moffitt Cancer Center, Tampa, Florida., Komrokji R; Malignant Hematology Department, Moffitt Cancer Center, Tampa, Florida., Haura E; Department of Drug Discovery, H Lee Moffitt Cancer Center, Tampa, Florida., Sallman DA; Malignant Hematology Department, Moffitt Cancer Center, Tampa, Florida., Reuther GW; Department of Molecular Oncology, H Lee Moffitt Cancer Center, Tampa, Florida., Karsan A; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC., Rix U; Department of Drug Discovery, H Lee Moffitt Cancer Center, Tampa, Florida., Patnaik MM; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota., Padron E; Malignant Hematology Department, Moffitt Cancer Center, Tampa, Florida.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Aug 01; Vol. 29 (15), pp. 2919-2932.